Patrick Schöffski

43.5k total citations · 7 hit papers
510 papers, 19.4k citations indexed

About

Patrick Schöffski is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Patrick Schöffski has authored 510 papers receiving a total of 19.4k indexed citations (citations by other indexed papers that have themselves been cited), including 315 papers in Pulmonary and Respiratory Medicine, 224 papers in Oncology and 136 papers in Gastroenterology. Recurrent topics in Patrick Schöffski's work include Sarcoma Diagnosis and Treatment (162 papers), Gastrointestinal Tumor Research and Treatment (136 papers) and Gastric Cancer Management and Outcomes (78 papers). Patrick Schöffski is often cited by papers focused on Sarcoma Diagnosis and Treatment (162 papers), Gastrointestinal Tumor Research and Treatment (136 papers) and Gastric Cancer Management and Outcomes (78 papers). Patrick Schöffski collaborates with scholars based in Belgium, Germany and United States. Patrick Schöffski's co-authors include Jean‐Yves Blay, Maria Dêbiec‐Rychter, Agnieszka Woźniak, Raf Sciot, Herlinde Dumez, Jaap Verweij, Hans Gelderblom, Pascal Wolter, Sandrine Marréaud and Axel Le Cesne and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Patrick Schöffski

492 papers receiving 19.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib in Progressive Medullary Thyroid Cancer

2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

2014 814 citations Jaap Verweij, Patrick Schöffski et al. profile →
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

2004 616 citations Patrick Schöffski et al. Journal of Clinical Oncology profile →
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

2016 539 citations Patrick Schöffski, Sant P. Chawla et al. profile →
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

2009 535 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 429 citations Luc Dirix, Patrick Schöffski et al. profile →
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

2020 251 citations Jean‐Yves Blay, Patrick Schöffski et al. profile →

Peers

Countries citing papers authored by Patrick Schöffski

Since Specialization

Citations

This map shows the geographic impact of Patrick Schöffski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Schöffski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Schöffski more than expected).

Fields of papers citing papers by Patrick Schöffski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Schöffski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Schöffski. The network helps show where Patrick Schöffski may publish in the future.

Co-authorship network of co-authors of Patrick Schöffski

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Schöffski. A scholar is included among the top collaborators of Patrick Schöffski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Schöffski. Patrick Schöffski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anagrelide for Gastrointestinal Stromal Tumor 2018 ·Clinical Cancer Research ·(unknown), Yemarshet K. Gebreyohannes, Agnieszka Woźniak, (unknown), Olli Tynninen, (unknown), Alejandra Cervera, Salla Keskitalo, Astrid Murumägi, Evgeny Kulesskiy, (unknown), Krister Wennerberg, Markku Varjosalo, Pirjo Laakkonen, Rainer Lehtonen, Sampsa Hautaniemi, Olli Kallioniemi, Patrick Schöffski, Harri Sihto, Heikki Joensuu	19
2	In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models 2017 ·Molecular Cancer Therapeutics ·Jasmien Cornillie, Agnieszka Woźniak, Péter Pokreisz, Andrea Casazza, (unknown), Jasmien Wellens, Ulla Vanleeuw, Yemarshet K. Gebreyohannes, Maria Dêbiec‐Rychter, Raf Sciot, Daphne Hompes, Patrick Schöffski	16
3	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine 2017 ·Journal of Clinical Oncology ·George D. Demetri, Patrick Schöffski, Giovanni Grignani, Jean‐Yves Blay, Robert G. Maki, Brian A. Van Tine, Thierry Alcindor, Robin L. Jones, David R. D’Adamo, Matthew Guo, Sant P. Chawla	129
4	Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations 2016 ·Molecular Cancer Therapeutics ·Yemarshet K. Gebreyohannes, Patrick Schöffski, Thomas Van Looy, Jasmien Wellens, (unknown), Jasmien Cornillie, Ulla Vanleeuw, Dana T. Aftab, Maria Dêbiec‐Rychter, Raf Sciot, Agnieszka Woźniak	29
5	Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study 2014 ·Clinical Cancer Research ·Víctor Moreno, David Olmos, Carlos Gomez‐Roca, Philippe A. Cassier, Rafael Morales‐Barrera, (unknown), Elisa Gallerani, André T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile E. Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye	14
6	Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors 2014 ·Cancer Research ·Sergei Boichuk, (unknown), (unknown), Kathleen R. Makielski, Agnieszka Woźniak, Danushka S. Seneviratne, Nina Korzeniewski, Rolando Cuevas, Joshua A. Parry, Matthew F. Brown, James P. Zewe, Takahiro Taguchi, (unknown), Patrick Schöffski, Maria Dêbiec‐Rychter, Anette Duensing	37
7	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST 2014 ·Clinical Cancer Research ·Agnieszka Woźniak, Piotr Rutkowski, Patrick Schöffski, Isabelle Ray‐Coquard, Isabelle Hostein, Hans‐Ulrich Schildhaus, Axel Le Cesne, Elżbieta Bylina, Janusz Limon, Jean‐Yves Blay, Janusz A. Siedlecki, Eva Wardelmann, Raf Sciot, Jean‐Michel Coindre, Maria Dêbiec‐Rychter	121
8	Cabozantinib in Progressive Medullary Thyroid Cancer breakdown → 2013 ·Journal of Clinical Oncology ·Rossella Elisei, Martin Schlumberger, Stefan Müller, Patrick Schöffski, Marcia S. Brose, Manisha H. Shah, Lisa Licitra, Barbara Jarząb, В. С. Медведев, Michael C. Kreißl, Bruno Niederle, Ezra E.W. Cohen, Lori J. Wirth, Haythem Ali, Colin Hessel, Yifah Yaron, Douglas W. Ball, Barry D. Nelkin, Steven I. Sherman	850
9	The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis 2013 ·Cancer Research ·Sergei Boichuk, Joshua A. Parry, Kathleen R. Makielski, Larisa Litovchick, Julianne L. Baron, James P. Zewe, Agnieszka Woźniak, (unknown), Nina Korzeniewski, Danushka S. Seneviratne, Patrick Schöffski, Maria Dêbiec‐Rychter, James A. DeCaprio, Anette Duensing	77
10	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 2012 ·Clinical Cancer Research ·José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Federico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, (unknown), (unknown), Margaret Dugan, Kathryn Parker, Eric Walk, A. van Oosterom, Erika Martinelli, Chris H. Takimoto	14
11	The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models 2012 ·Molecular Cancer Therapeutics ·Tomoko Smyth, Thomas Van Looy, Jayne Curry, Ana M. Rodrı́guez-López, Agnieszka Woźniak, Mei‐Jun Zhu, (unknown), (unknown), Mark Mayeda, Jonathan A. Fletcher, Patrick Schöffski, John F. Lyons, Neil T. Thompson, Nicola G. Wallis	49
12	A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal 2012 ·Clinical Cancer Research ·Giuseppe Floris, Agnieszka Woźniak, Raf Sciot, Haifu Li, Lori S. Friedman, Thomas Van Looy, Jasmien Wellens, Peter Vermaelen, Christophe M. Deroose, Jonathan A. Fletcher, Maria Dêbiec‐Rychter, Patrick Schöffski	59
13	The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations 2011 ·Clinical Cancer Research ·Giuseppe Floris, Raf Sciot, Agnieszka Woźniak, Thomas Van Looy, Jasmien Wellens, Gavino Faa, Emmanuel Normant, Maria Dêbiec‐Rychter, Patrick Schöffski	41
14	Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors 2011 ·Clinical Cancer Research ·Pauline Lagarde, Gaëlle Pérot, Audrey Kauffmann, Céline Brulard, (unknown), Isabelle Hostein, Agnès Neuville, Agnieszka Woźniak, Raf Sciot, Patrick Schöffski, Alain Aurias, Jean‐Michel Coindre, Maria Dêbiec‐Rychter, Frédéric Chibon	102
15	A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, José A. López-Martín, Jaume Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett M. Hall, Zhilong Yuan, Roland E. Knoblauch, Sen Hong Zhuang	46
16	The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors 2011 ·Molecular Cancer Therapeutics ·Giuseppe Floris, Maria Dêbiec‐Rychter, Agnieszka Woźniak, Cristiana Stefan, Emmanuel Normant, Gavino Faa, Kathleen Machiels, Ulla Vanleeuw, Raf Sciot, Patrick Schöffski	37
17	Coactivated Platelet-Derived Growth Factor Receptor α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma 2010 ·Cancer Research ·Barbara Dewaele, Giuseppe Floris, (unknown), Christopher Fletcher, Jean‐Michel Coindre, Louis Guillou, Pancras C.W. Hogendoorn, Agnieszka Woźniak, Vanessa Vanspauwen, Patrick Schöffski, Peter Marynen, Peter Vandenberghe, Raf Sciot, Maria Dêbiec‐Rychter	68
18	Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure 2009 ·Clinical Cancer Research ·Samuel E. DePrimo, Xin Huang, Martin E. Blackstein, Christopher R. Garrett, Charles S. Harmon, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Charles M. Baum, George D. Demetri	38
19	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) breakdown → 2009 ·Journal of Clinical Oncology ·Stefan Sleijfer, Isabelle Ray‐Coquard, Zsuzsa Pápai, Axel Le Cesne, Michelle Scurr, Patrick Schöffski, Françoise Collin, Lini Pandite, Sandrine Marréaud, (unknown), M. van Glabbeke, Jaap Verweij, Jean‐Yves Blay	535
20	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model 2009 ·Clinical Cancer Research ·Giuseppe Floris, Maria Dêbiec‐Rychter, Raf Sciot, Cristiana Stefan, Steffen Fieuws, Kathleen Machiels, Peter Atadja, Agnieszka Woźniak, Gavino Faa, Patrick Schöffski	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact